Istanbul, Turkey, 2–4 November 2023 — MicroPort EP proudly participated in the 17th World Congress of Arrhythmias (WSA), an internationally renowned conference in heart rhythm disorders, often hailed as the “Olympic event” of the field with significant influence in the industry. MicroPort EP invited experts to the quadrennial WSA for academic discussions and to showcase its innovative product portfolio.
This year, WSA focused on treatments for arrhythmias, covering various cutting-edge technological fields and centered on the current unmet clinical needs and other hot topics. Over 50 experts from nearly 20 countries visited and experienced MicroPort EP’s product portfolio, which included the Columbus™ 3D EP Navigation System V3 (Columbus™ System V3), along with its accompanying FireMagic™ TrueForce™ Ablation Catheter (TrueForce™ Ablation Catheter) and other products in the series. Many experts expressed appreciation for the unique feature of TrueForce™ Ablation Catheter’s Quantitative Ablation Index (EI) and Columbus™ System V3’s Smart Label automatic point acquisition.
In collaboration with WSA, MicroPort EP co-hosted an academic meeting titled “A Novel Approach to Contact Force Sensing Technique: Strain Gauge Based Technique,” which provided a platform for academic exchange for electrophysiology experts from different countries. The meeting was chaired by Professor Yan Yao, President of the Asian Society of Cardiac Rhythm and Director of the Arrhythmia Center at Fuwai Hospital of the Chinese Academy of Medical Sciences, and Dr. Jose Luis Merino, President of the European Heart Rhythm Association.
During the meeting, Professor Yan Yao, and Dr. Emin, Dr. Can from Turkey discussed the technological advantages and clinical application experiences of the FireMagic™ TrueForce™ Ablation Catheter by sharing clinical cases and exchanging academic insights on the current state and future direction of atrial fibrillation diagnosis and treatment technologies. Dr. Emin, who recently used the FireMagic™ TrueForce™ Ablation Catheter to complete treatment procedures for two cases of atrial fibrillation and one case of atrial flutter, highly praised the device’s performance.
So far, MicroPort EP’s products have been exported to more than 30 countries and regions. MicroPort EP will enhance its global market presence by providing more comprehensive products and professional services for electrophysiological interventions and treatments.
About MicroPort EP
Founded in 2010, MicroPort EP (Shanghai MicroPort EP MedTech Co., Ltd; SSE: 688351), an associated company of MicroPort® (MicroPort Scientific Corporation; HKEX: 00853), is a global medical devices company focusing on the development, manufacturing, and marketing minimally invasive medical devices for the treatment of cardiac arrhythmia. It has developed a family of advanced cardiac ablation catheters, diagnostic catheters, and 3D navigation systems. These solutions are used by hundreds of physicians at over 900 hospitals over more than 30 countries. At MicroPort EP, we strive to provide integrated therapeutic solutions to apply precise navigation on interventional procedures, dedicated to providing high quality therapeutic solutions to patients and physicians across the globe.
More information is available at www.everpace.com.